AzTrials
AzTrials

Rheumatoid ArthritisPhase 3NCT00754572

A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

A Phase 3 study testing tocilizumab [RoActemra/Actemra] and methotrexate in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 69 sites in 10 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This single arm, open-label study will assess the safety and efficacy with regar d to reduction of signs and symptoms of treatment with tocilizumab in combinatio n with methotrexate, in patients with moderate to severe active rheumatoid arthr itis. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
tocilizumab [RoActemra/Actemra] and methotrexate
Could I receive a placebo?
No, everyone receives an active treatment
How many people
418 participants
Where
69 sitesin 10 countries
Study dates
Feb 2009to Oct 2012
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • patients >=18 years with moderate to severe active RA for at least 6 months;
  • swollen joint count >=6 (66 joint count) and tender joint count >=8 (68 joint count) at screening;
  • inadequate response to stable dose of MTX;
  • patients of reproductive potential must be using a reliable means of contraception.

Who cannot join

  • rheumatic autoimmune disease other than RA;
  • patients with functional class IV RA;
  • diagnosis of juvenile idiopathic or rheumatoid arthritis before age 16 or a history of current inflammatory joint disease other than RA;
  • prior treatment failure with anti-tumor necrosis factor agent;
  • pregnant or breastfeeding women.

Trial locations and contacts

69 sites in 10 countries.

69 sites in 10 countries

Brazil22 sites
  • Study site

    Belo Horizonte, Minas Gerais, 30150-221

  • Study site

    Botucatu, São Paulo, 18600-400

  • Study site

    Brasília, Federal District, 70840-901

  • Study site

    Campinas, São Paulo, 13059-900

  • Study site

    Campinas, São Paulo, 13083-888

  • Study site

    Caxias do Sul, Rio Grande do Sul, 95070-560

  • Study site

    Curtiba, Paraná, 80030-110

  • Study site

    Florianópolis, Santa Catarina, 88040-970

  • Study site

    Fortaleza, Ceará, 60170001

  • Study site

    Juiz de Fora, Minas Gerais, 36010-570

  • Study site

    Porto Alegre, Rio Grande do Sul, 90035-003

  • Study site

    Porto Alegre, Rio Grande do Sul, 90610-000

  • Study site

    Recife, Pernambuco, 50000-000

  • Study site

    Ribeirão Preto, São Paulo, 14048-900

  • Study site

    Rio de Janeiro, Rio de Janeiro, 20551-030

  • Study site

    Salvador, Estado de Bahia, 40050-410

  • Study site

    Santo André, São Paulo, 09060-650

  • Study site

    São José do Rio Preto, São Paulo, 15090-000

  • Study site

    São Paulo, São Paulo, 04027-000

  • Study site

    São Paulo, São Paulo, 04039-004

  • Study site

    São Paulo, São Paulo, 04266-010

  • Study site

    Vitória, Espírito Santo, 29043-910

Other trials in Brazil

Chile8 sites
  • Study site

    Concepción, 1436

  • Study site

    Santiago, 352

  • Study site

    Santiago, 7500000

  • Study site

    Santiago, 7550000

  • Study site

    Santiago, 8320000

  • Study site

    Santiago, 8380000

  • Study site

    Santiago, 8860000

  • Study site

    Temuco, 4780000

Other trials in Chile

Colombia8 sites
  • Study site

    Barranquilla

  • Study site

    Bogotá, 49 00

  • Study site

    Bogotá

  • Study site

    Bucaramanga, 0

  • Study site

    Cali

  • Study site

    Chia-Cundinamarca

  • Study site

    Medellín, 0

  • Study site

    Medellín

Other trials in Colombia

Mexico8 sites
  • Study site

    Chihuahua City, 31238

  • Study site

    Guadalajara, 44650

  • Study site

    Mexico City, 03900

  • Study site

    Mexico City, 11850

  • Study site

    Mexico City, 14140

  • Study site

    Miexico City, 06700

  • Study site

    Querétaro, 76000

  • Study site

    San Luis Potosí City, 78240

Other trials in Mexico

Argentina6 sites
  • Study site

    Buenos Aires, C1280AEB

  • Study site

    Buenos Aires, C1425ASQ

  • Study site

    Buenos Aires, C1426AAL

  • Study site

    Córdoba, X5000FAL

  • Study site

    San Miguel, T4000AXL

  • Study site

    San Miguel de Tucumán, T4000IFP

Other trials in Argentina

Costa Rica4 sites
  • Study site

    Cartago, 0

  • Study site

    Heredia, 00

  • Study site

    San José, 10103

  • Study site

    San José

Other trials in Costa Rica

Ecuador4 sites
  • Study site

    Cuenca

  • Study site

    Guayaquil

  • Study site

    Quito, EC170517

  • Study site

    Quito

Other trials in Ecuador

Peru4 sites
  • Study site

    Arequipa, 04001

  • Study site

    Jesus Maria

  • Study site

    Lima, LIMA 14

  • Study site

    San Isidro, Lima 27

Other trials in Peru

Venezuela4 sites
  • Study site

    Barquisimeto, 3005

  • Study site

    Caracas, 1010

  • Study site

    Caracas, 1040

  • Study site

    Maracaibo, 4001

Other trials in Venezuela

Uruguay1 site
  • Study site

    Montevideo, 11000

Other trials in Uruguay

About this study

Official title: A Single-arm, Open-label Study of the Safety and Reduction of Signs and Symptoms During Treatment With Tocilizumab in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis

This single arm, open-label study will assess the safety and efficacy with regar d to reduction of signs and symptoms of treatment with tocilizumab in combinatio n with methotrexate, in patients with moderate to severe active rheumatoid arthr itis. Patients will receive tocilizumab 8mg/kg iv, every 4 weeks and methotrexat e 10-25mg weekly. The anticipated time on study treatment is 3-12 months, and th e target sample size is <500 individuals.

Being tested
tocilizumab [RoActemra/Actemra], methotrexate
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • tocilizumab [RoActemra/Actemra]Drug

    8mg/kg iv, every 4 weeks

  • methotrexateDrug

    10-25mg oral or parenteral weekly.

Study groups in NCT00754572
Study groupRoleWhat they receive
1ExperimentalNot described
Receives: Drug: tocilizumab [RoActemra/Actemra]; Drug: methotrexate

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 24

    ACR50 is defined as 50 percent (%) improvement in: a) Swollen Joints Count (SJC) and Tender Joints Count (TJC) and b) Three of the following 5 assessments:

    1. Participant's global assessment of pain by Visual Analog Scale (VAS)
    2. Participant's global assessment of disease activity (VAS)
    3. Investigator/Physician's global assessment of disease activity (VAS)
    4. Participant's assessment of disability measured by the Health Assessment Questionnaire Disability Index (HAQ-DI)
    5. Acute phase reactant levels - Erythrocyte Sedimentation Rate or C-Reactive Protein (ESR or CRP)

    Measured: Week 24

Secondary outcomes (23)
  1. Percentage of Participants With ACR20 and ACR70 Response at Week 24

    ACR20 and ACR70 are defined as 20 and 70 percent improvement respectively in: a) SJC and TJC and b) Three of the following 5 assessments:

    1. Participant's global assessment of pain by VAS
    2. Participant's global assessment of disease activity (VAS)
    3. Investigator/Physician's global assessment of disease activity (VAS)
    4. Participant's assessment of disability measured by HAQ-DI
    5. Acute phase reactant (ESR or CRP)

    Measured: Week 24

  2. Time to Onset of ACR20, ACR50, and ACR70

    ACR20, ACR50 and ACR70 are defined as 20, 50 and 70 percent improvement respectively in: a) SJC and TJC and b) Three of the following 5 assessments:

    1. Participant's global assessment of pain by VAS
    2. Participant's global assessment of disease activity (VAS)
    3. Investigator/Physician's global assessment of disease activity (VAS)
    4. Participant's assessment of disability measured by HAQ-DI
    5. Acute phase reactant (ESR or CRP)

    Measured: Baseline and Week 24

  3. Change From Baseline in Hemoglobin at Week 24

    Measured: Baseline and Week 24

  4. SJC and TJC at Baseline and Week 24

    The number of swollen joints (66 joint count) were scored as swollen=1 and not swollen=0, and the number of tender joints (68 joint count ) were scored as tender=1 and not tender=0, and counted. Scores ranged from 0 to 66 for swollen joint counts and from 0 to 68 for tender joint counts. A positive change from baseline represents an improvement (a reduction in the number of swollen or tender joints).

    Measured: Baseline and Week 24

  5. Percent Change From Baseline in SJC and TJC at Week 24

    The number of swollen joints (66 joint count) were scored as swollen=1 and not swollen=0, and the number of tender joints (68 joint count ) were scored as tender=1 and not tender=0, and counted. Scores ranged from 0 to 66 for swollen joint counts and from 0 to 68 for tender joint counts. A positive change from baseline represents an improvement (a reduction in the number of swollen or tender joints).

    Measured: Baseline and Week 24

  6. Pain as Assessed by the Participant at Baseline and Week 24

    The participants assessed their pain using a 0 to 100 millimeter (mm) VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". The participants marked the line corresponding to the level of their pain and the distance from the left edge was measured. A positive change from baseline represents an improvement.

    Measured: Baseline and Week 24

  7. Percent Change From Baseline in Pain as Assessed by the Participant at Week 24

    The participants assessed their pain using a 0 to 100 millimeter (mm) VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". The participants marked the line corresponding to the level of their pain and the distance from the left edge was measured. A positive change from baseline represents an improvement.

    Measured: Baseline and Week 24

  8. Participant's Global Assessment of Disease Activity at Baseline and Week 24

    The participant's global assessment of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A positive change from baseline represents an improvement (reduced level of disease activity).

    Measured: Baseline and Week 24

  9. Percent Change From Baseline in Participant's Global Assessment of Disease Activity at Week 24

    The participant's global assessment of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A positive change from baseline represents an improvement (reduced level of disease activity).

    Measured: Baseline and Week 24

  10. Physician's Global Assessment of Disease Activity at Baseline and Week 24

    The physician's global assessment of disease activity is assessed on a 0 to 100 mm VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). The physicians marked the line corresponding to their assessment and the distance from the left edge was measured. A positive change from baseline represents an improvement (reduced level of disease activity).

    Measured: Baseline and Week 24

  11. Percent Change From Baseline in Physician's Global Assessment of Disease Activity at Week 24

    The physician's global assessment of disease activity is assessed on a 0 to 100 mm VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). The physicians marked the line corresponding to their assessment and the distance from the left edge was measured. A positive change from baseline represents an improvement (reduced level of disease activity).

    Measured: Baseline and Week 24

  12. HAQ-DI at Baseline and Week 24

    HAQ-DI includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0 =without difficulties; 1= with some difficulties; 2=with great difficulties; and 3= unable to perform these actions at all. Minimum score was 0, maximum score was 3. A positive change from baseline represents an improvement (reduced level of impairment).

    Measured: Baseline and Week 24

  13. Percent Change From Baseline in HAQ-DI at Week 24

    HAQ-DI includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3. A positive change from baseline represents an improvement (reduced level of impairment).

    Measured: Baseline and Week 24

  14. Area Under The Curve (AUC) of the ACR(n)

    ACR-n was defined as the lowest of 3 values (the percent change in the swollen joint count, the percent change in the tender joint count, and the median of the other 5 measures in the ACR core data set which included Participant's global assessment of pain (VAS), Participant's global assessment of disease activity (VAS), Investigator/Physician's global assessment of disease activity (VAS), Participant's assessment of disability measured by the HAQ-DI Acute phase reactant levels - ESR or CRP). Therefore, a percentage value was assigned to each participant at each timepoint. AUC was calculated for each participant from baseline to Week 112. Mean and standard deviation values are are provided in percent*years.

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  15. Percentage of Participants Achieving ACR20 Response

    ACR20 is defined as 20% improvement in: a) SJC and TJC and b) Three of the following 5 assessments:

    1. Participant's global assessment of pain (VAS)
    2. Participant's global assessment of disease activity (VAS)
    3. Investigator/Physician's global assessment of disease activity (VAS)
    4. Participant's assessment of disability measured by the HAQ-DI
    5. Acute phase reactant levels - ESR or CRP

    Measured: Week 2

  16. Odds Estimates for ACR Positive Response in Generalized Estimating Equation (GEE) Models

    The probability of ACR positive response was determined using the GEE.

    Measured: Weeks 2, 4, 8, 12, 16, 20, 24

  17. Change From Baseline in Disease Activity Score Based on 28 Joint Count (DAS28) at Week 24

    DAS28 calculated from the number of SJC and TJC using the 28 joints count, the ESR (mm/hour) and participant's global assessment of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 (less than or equal to ) ≤3.2 = low disease activity, DAS28 (greater than) >3.2 to 5.1 = moderate to high disease activity.

    Measured: Baseline and Week 24

  18. Percentage of Participants With a Response by Categorical DAS28 Responses According to The European League Against Rheumatism (EULAR Response) at Week 24

    DAS28- based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good response: change from baseline >1.2 with DAS28 < 3.2; moderate response: change from baseline >1.2 with DAS28 >3.2 to <5.1 or change from baseline >0.6 to <1.2 with DAS28 <5.1; No response: change from baseline < 0.6 or change from baseline >0.6 and <1.2 with DAS28 >5.1.

    Measured: Week 24

  19. AUC of DAS28

    The AUC was computed using the trapezoidal rule, considering baseline value as 0, through NCSS software. For each participant, AUC for DAS28 units was calculated. Each individual AUC DAS28 value was divided by 52 to have the conversion of AUC DAS28 in unit weeks to AUC DAS28 in unit years, as 1 week is approximately 1/52 years. The set of individual AUC DAS28 was computed as summary statistics.

    Measured: Weeks 2, 4, 8, 12, 16, 20 and 24

  20. Fatigue as Assessed Using the Functional Assessment of Chronic Illness Therapy (FACIT-Fatigue) Score at Week 24

    FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflects an improvement in the participant's health status.

    Measured: Week 24

  21. Percentage of Participants Achieving Remission (DAS28 Less Than [<] 2.6) at Week 24

    DAS28 calculated from the SJC and TJC using the 28 joints count, the ESR (mm/hour) and participant's global assessment of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 (less than or equal to ) ≤3.2 = low disease activity, DAS28 (greater than) >3.2 to 5.1 = moderate to high disease activity and DAS28<2.6 = remission

    Measured: Week 24

  22. Quality of Life (QoL) Assessed by Short-Form 36 (SF-36) at Week 24

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. Total of 3 variables were analyzed (2 composite subscales and vitality score). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).

    Measured: Week 24

  23. Mean Change in Rheumatoid Factor (RF) at Week 24 in Participants With Positive RF

    Measured: Baseline and Week 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Sep 2008 (estimated)
  2. Study startFeb 2009
  3. Primary completionOct 2012
  4. Study completionOct 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
418 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00754572
Sponsor's protocol ID
ML21530
Status last verified
May 2015
First submitted
17 Sep 2008
Last updated
15 May 2015

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing tocilizumab [RoActemra/Actemra] and methotrexate in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 69 sites in 10 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 May 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 69 sites in Brazil, Chile, Colombia, Mexico, Argentina and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 15 May 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 24 (time frame: Week 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in